KBI2025 Anti-Ipilimumab ELISA Assay Kit

Anti-Ipilimumab ELISA Assay Kit

$1,810.00

The Anti-Ipilimumab ELISA Assay Kit is intended as an analytical tool for quantitative determination of Anti-Ipilimumab in serum, plasma, and cell culture supernatant.

SKU: KBI2025 Category:

Anti-Ipilimumab ELISA Assay Kit

The Anti-Ipilimumab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: <10 ng/ml
Standard Range: 10-640 ng/ml
Incubation Time: 2.25 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µl
Alternative Name: Yervoy

Assay Background

Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that down regulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function. Ipilimumab was approved by the U.S. FDA in 2011 for the treatment of melanoma, a type of skin cancer. It is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), bladder cancer and metastatic hormone-refractory prostate cancer. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals.
Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Ipilimumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Ipilimumab and may be used for monitoring immunogenicity.

Related Products

Ipilimumab ELISA Assay Kit
Anti-Denosumab ELISA Assay
Anti-Atezolizumab (Tecentriq) ELISA Assay Kit

Additional Information

Assay Principle

The method employs the quantitative sandwich enzyme immunoassay technique. Ipilimumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Ipilimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Ipilimumab is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Ipilimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations